Compare Heron Therapeutics Inc (HRTX) vs JetBlue Airways Corporation (JBLU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs JetBlue Airways Corporation — how do they compare? Heron Therapeutics Inc trades at $0.32 (market cap $63.41M), while JetBlue Airways Corporation trades at $5.81 (market cap $2.13B). The key difference: JetBlue Airways Corporation is far larger — about 33.6× Heron Therapeutics Inc's market cap, and JetBlue Airways Corporation is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | JBLU | |
|---|---|---|
Market Cap | $63.41M | $2.13B |
Sector | Health | Industrials |
52-Week High | $1.49 | $6.46 |
52-Week Low | $0.32 | $4.03 |
Enterprise Value | $161.31M | $9.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.
HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.
JetBlue (JBLU) trades at $6.07, down 1.94% today, with mixed technical signals showing bullish moving averages but neutral oscillators. The company reported a Q2 2026 earnings beat but continues to post net losses, with negative profit margins and declining revenue trends. Recent news includes analyst downgrades from Citigroup citing geopolitical risks, though the company has introduced new fare structures and lounge enhancements to drive growth.
The outlook remains challenging with persistent losses and high debt levels, though cost management and strategic initiatives offer potential upside. Key risks include fuel cost volatility, competitive pressures, and execution of the 2028 profit target. Analyst consensus is cautious with a $5.18 price target below current levels, reflecting skepticism about near-term profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →
